BlossomHill Therapeutics, Inc. BLSM
Set alert
At close · Oct 30
After hours · Oct 30, 5:01 PM ET
- YTD
- -14.06%
- 1 year
- -14.06%
- Open
- 16.40
- Prev close
- 15.21
- Mkt cap
- 437.04M
- Vol
- 156.30K
- Avg vol
- 227.95K
- EPS
- -4.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.51
- High
- 16.40
News
4 days ago seekingalpha.com
BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price
BlossomHill Therapeutics achieved major de-risking milestones within 80 days post-IPO, including Fast Track and a key companion diagnostic partnership. I see the C797S lung cancer indication as a…
-
1 week ago benzinga.com
BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines…
1 week ago globenewswire.com
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and…
1 month ago defenseworld.net
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 4.9% – Time to Sell?
BlossomHill Therapeutics, Inc. (NASDAQ: BLSM - Get Free Report)'s share price traded down 4.9% on Wednesday. The stock traded as low as $20.33 and last traded at $20.33. Approximately 22,349 shares…
1 month ago defenseworld.net
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – Here’s Why
BlossomHill Therapeutics, Inc. (NASDAQ: BLSM - Get Free Report) shares gapped up before the market opened on Tuesday. The stock had previously closed at $19.75, but opened at $21.17. BlossomHill…
-
1 month ago benzinga.com
BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND…
1 month ago globenewswire.com
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND…
-
1 month ago benzinga.com
Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40
Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.
-
1 month ago benzinga.com
Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40
Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy and raises the price target from $30 to $40.
1 month ago benzinga.com
Earnings Scheduled For September 18, 2026
Companies Reporting Before The Bell • BlossomHill Therapeutics (NASDAQ:BLSM) is expected to report earnings for its second quarter. Companies Reporting After The Bell This article was generated by…
-
1 month ago benzinga.com
BlossomHill Therapeutics Q2 EPS $(8.75)
BlossomHill Therapeutics (NASDAQ:BLSM) reported quarterly losses of $(8.75) per share. This is a 58.8 percent decrease over losses of $(5.51) per share from the same period last year.
1 month ago globenewswire.com
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR…
-
1 month ago benzinga.com
BlossomHill Therapeutics Announces Updated Data From Ongoing Phase 1/2 SOLARA Trial Of BH-30643 In NSCLC Patients With Secondary EGFR Resistance Mutations Such As EGFR C797S
45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat…
1 month ago globenewswire.com
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat…
1 month ago defenseworld.net
BlossomHill Therapeutics, Inc.’s Quiet Period Set To Expire on September 16th (NASDAQ:BLSM)
BlossomHill Therapeutics' (NASDAQ: BLSM - Get Free Report) quiet period will end on Wednesday, September 16th. BlossomHill Therapeutics had issued 9,375,000 shares in its public offering on August…
1 month ago globenewswire.com
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and…
-
2 months ago benzinga.com
LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32
LifeSci Capital initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform rating and announces Price Target of $32.
-
2 months ago benzinga.com
Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36
Leerink Partners initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform rating and announces Price Target of $36.
-
2 months ago benzinga.com
JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28
JP Morgan analyst Brian Cheng initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Overweight rating and announces Price Target of $28.
-
2 months ago benzinga.com
Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30
Guggenheim analyst Michael Schmidt initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $30.
2 months ago benzinga.com
This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
2 months ago globenewswire.com
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast…
-
2 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $35
HC Wainwright & Co. analyst Robert Burns initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $35.
-
2 months ago benzinga.com
Blossomhill Says FDA Grants Fast Track Designation To BH-30643 For Treatment Of Adult Patients With Advanced Or Metastatic EGFR C797S-Positive NSCLC After Prior Treatment With Third-Gen EGFR Tyrosine Kinase Inhibitor
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines…
2 months ago globenewswire.com
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and…
2 months ago defenseworld.net
BlossomHill Therapeutics (NASDAQ:BLSM) Director Bihua Chen Purchases 312,500 Shares of Stock
BlossomHill Therapeutics, Inc. (NASDAQ: BLSM - Get Free Report) Director Bihua Chen acquired 312,500 shares of the business's stock in a transaction dated Monday, August 10th. The shares were bought…
2 months ago globenewswire.com
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based…
2 months ago seekingalpha.com
BlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline Promise
BlossomHill Therapeutics is seeking a $125 million IPO to advance its oncology pipeline, focused on EGFR-mutant NSCLC. I see early clinical data for BH-30643 as promising, supporting a potential…